POSTER SESSION IV Tuesday, March 9, 2004   —  1:00 - 4:30 PM Exhibit Hall B and C GENITOURINARY PATHOLOGY 59 Androgen Receptor (AR) Expression in Urothelial Carcinoma of Bladder (639) R Gandour-Edwards, JL Chen, T Simcox, X-B Shi, JM LaSalle, PN Lara, RW deVere - White University of California Davis, Sacramento, CA 60 Stability of the FGFR3 Mutant Status in Urothelial Cell Carcinoma Recurrences (766) TH van der Kwast, MNM van der Aa, TJA van Exsel, BW van Rhijn, EC Zwarthoff - Erasmus MC, Rotterdam, Netherlands 61 Evaluation of Differential Expression of Estrogen Receptors a and b in Bladder Cancers by Tissue Microarray (742) SS Shen, W Jian, Y Jiang, M Chirala, M Sayeeduddin, G Ayala, M Younes, SP Lerner - Baylor College of Medicine, Houston, TX 62 pTa Bladder Carcinomas Show Different Genetic Alterations Compared to pT1 and pT2 Carcinomas. A Fluorescence In Situ Hybridization Study (602) M Castillo, M Sole, M Santos, JM Corral, JB Alcover, C Mallofre - Hospital Clinic. IDIBAPS. Universitat de Barcelona, Barcelona, Spain 63 Overexpression of Human Carcinoma-Associated Antigen (HCA) in Urothelial Carcinoma of the Bladder (776) JL Yao, R Li, PA Bourne, JY Lei, PA di Sant'Agnese, J Huang - University of Rochester Medical Center, Rochester, NY 64 EphA2: A Novel Target for the Treatment of Bladder Cancer (600) MD Carr, S Abraham, L Cheng, M Kinch, D Knapp, S Mohammed - Indiana University School of Medicine, Indianapolis, IN; Purdue University, West Laffayette, IN; Medimmune Inc., Gaithersburg, MD 65 Pathological Stages of Radical Cystectomy: Comparison of Clinicopathological Features and Molecular Marker Profiles of Lower and Higher Stage Tumors (741) R Shen, H Zhang, G Bently, R Ali, F Bianco, W Sakr, D Grignon, M Che - Harper University Hospital, the Karmanos Cancer Institute and Wayne State University, Detroit, MI 66 Chromophobe Renal Cell Carcinoma: Clinicopathologic Study of 146 Cases at a Single Institution (611) F Darvishian, S Olgac, S Tickoo, P Russo, VE Reuter - Memorial Sloan-Kettering Cancer Center, New York, NY; WMC of Cornell University, New York, NY 67 Comparison of C-kit Expression in Chromophobe Renal Cell Carcinoma and Renal Oncocytoma (664) L Huo, BP Adley, KT Patton, J Sugimura, BT Teh, XJ Yang - Feinberg School of Medicine, Northwestern University, Chicago, IL; Van Andel Research Institute, Grand Rapids, MI 68 Kit Expression in Chromophobe Renal Cell Carcinoma and Oncocytoma. Comparative Immunohistochemical Analysis of KIT Expression in Different Renal Cell Neoplasms (695) C Mallofre, M Castillo, A Petit, B Mellado, JB Alcover, E Campo - Hospital Clinic. IDIBAPS. Universitat de Barcelona, Barcelona, Spain 69 Renal Oncocytomas Do Not Express Cytokeratin 14 (633) AL Folpe, BF Skinnider, M de Peralta-Venturina, MB Amin - Emory University, Atlanta, GA; Vancouver General Hospital, Vancouver, BC, Canada; Henry Ford Hospital, Detroit, MI 70 S100A1 Distinguishes Renal Oncocytoma from Chromophobe Renal Carcinoma (696) G Martignoni, M Brunelli, M Pea, M Chilosi, A Eccher, P Cossu Rocca, F Menestrina, F Bonetti - Universita' di Sassari, Italy; Universita'di Verona, Italy 71 Prediction of Extraprostatic Extension in the Neurovascular Bundle (NVB) Based on Prostate Needle Biopsy, PSA, and Digital Rectal Examination (763) T Tsuzuki, H Aydin, DJ Hernandez, B Trock, PC Walsh, JI Epstein - Johns Hopkins Hospital, Baltimore, MD 72 Morphology of Centrosomes in Prostate Cancer - Correlation with DNA-Ploidy and Gleason Score (754) MI Toma, K Friedrich, W Meyer, GB Baretton - Institute of Pathology, TU Dresden, Dresden, Germany 73 Prostate Needle Biopsy Reporting: How Are Urologists Using Pathology Reports To Guide Treatment of Prostate Cancer Patients? (732) MA Rubin, TA Bismar, S Curtis, JE Montie - Brigham and Women's Hospital, Boston, MA; Harvard Medical School; University of Michigan School of Medicine, Ann Arbor, MI 74 Impact of Pathologic Review of Prostatic Needle Biopsies on Treatment Options. A Clinicopathologic Study of 496 Cases (663) R Hung, J Sathya, D Daya - Henderson General Hospital, Hamilton, ON, Canada; Hamilton Regional Cancer Centre, Hamilton, ON, Canada 75 Trends in Gleason Grading in Germany: Evaluation Using Prostate Cancer Tissue Microarrays (597) M Burchardt, R Engers, M Meuller, T Burchardt, R Ackermann, HE Gabbert, JI Epstein, MA Rubin - Heinrich-Heine University, Duesseldorf, Germany; Johns Hopkins' Hospitals, Johns Hopkins' School of Medicine, Baltimore, MD; Brigham and Women's Hospital, Harvard Medical School, Boston, MA 76 Number and Location of Nucleoli and Presence of Mitotic Figures and Apoptotic Bodies as Diagnostic Features in Limited Prostate Cancer on Needle Biopsy (577) H Aydin, M Herawi, M Zhou, JI Epstein - The Johns Hopkins Hospital, Baltimore, MD 77 High-Grade PIN Diagnosed Following PSA Screening and Extended Prostate Needle Biopsy Protocols: Are Automatic Repeat Biopsies Really Necessary? (768) M Varma, DFR Griffiths, D Cochlin, H Kynaston - University Hospital of Wales, Cardiff, Wales, United Kingdom 78 Cost Effective Analysis of Prostate Biopsies (686) KK Lin, BE Staley, DR Bolick - Ameripath Utah, Sandy, UT 79 The Significance of Tumor Heterogeneity for Prediction of DNA Ploidy of Prostate Cancer (651) L Häggarth, G Auer, C Busch, L Egevad - St Göran Hospital, Stockholm, Sweden; Karolinska Institute, Stockholm, Sweden; University Hospital, Uppsala, Sweden; Karolinska Hospital, Stockholm, Sweden 80 Preoperative Prediction of Gleason Grade in Radical Prostatectomy Specimens (725) CK Poulos, J Daggy, L Cheng - Indiana University School of Medicine, Indianapolis, IN 81 Racial Differences in Tumor Volume and Gleason Score in T1c Prostate Cancer: Additional Evidence for Lowering the PSA Threshold for Biopsy in African American Men (736) RF Sanchez-Ortiz, CA Pettaway, RJ Babaian, J Lloreta, DA Johnson, P Troncoso - UT M. D. Anderson Cancer Center, Houston, TX; Universitat Pompeu Fabra, Hospital del Mar-IMAS-IMIM, Barcelona, Spain 82 Tertiary Gleason Pattern 5 Is a Moderate Predictor of Tumor Metastasis, but Not of Survival, Following Brachytherapy for Prostate Cancer (762) LD True, K Wallner - University of Washington, Seattle, WA 83 Prostate Cancer Biopsy and Prostatectomy Findings with Cancer Progression Rates in Men with Initial Needle Biopsies Positive for High-Grade Prostatic Intraepithelial Neoplasia (721) DM Pierson, ML Blute, H Zincke, RP Myers, TJ Sebo - Mayo Clinic, Rochester, MN 84 Preoperative PSA Is Correlated with Tumor Volume and Prostate Weight and Predictive of PSA Recurrence (596) PJ Bunde, MO Koch, RA Bihrle, TA Gardner, JN Eble, J Daggy, L Cheng - Indiana University School of Medicine, Indianapolis, IN 85 Expression of Inhibitors of Apoptosis Proteins (IAPs) and Their Inhibitor, Smac Protein, in Human Testis and Testicular Germ Cell Tumors (615) M Devouassoux-Shisheboran, N Berrah, C Mauduit, N Berger, JP Droz, P Chalabreysse, M Benahmed - Hopital de la Croix Rousse, Hospices Civils de Lyon; INSERM U407; Centre Hospitalier Lyon-Sud, Lyon, France 86 Preoperative Prediction of Small Volume Cancer (<0.5 cc) in Radical Prostatectomy Specimens (604) L Cheng, MO Koch, CK Poulos, TD Jones, JK Daggy - Indiana University School of Medicine, Indianapolis, IN 87 Diagnosing Metastatic Germ Cell Tumors Using OCT4 Immunohistochemistry (605) L Cheng - Indiana University School of Medicine, Indianapolis, IN 88 OCT4 Is a Sensitive and Specific Marker for Testicular Seminoma and Embryonal Carcinoma (670) TD Jones, TM Ulbright, JN Eble, L Cheng - Indiana University School of Medicine, Indianapolis, IN 89 Expression of CD10 in Testicular Tumours (578) CM Bacon, L Vo, MC Parkinson, A Freeman - University College London Hospitals NHS Trust, London, UK 90 Validation of Tissue Microarray Technology and Cytokeratin Immunohistochemistry in Diagnosing Testicular Germ Cell Neoplasms (709) EK Nomoto, FL Baehner, C Zaloudek - University of California, San Francisco, San Francisco, CA 91 OCT4 Immunostaining Is Useful in the Diagnosis of Intratubular Germ Cell Neoplasia (672) TD Jones, TM Ulbright, JN Eble, L Cheng - Indiana University, Indianapolis, IN 92 Sarcomatoid Carcinoma of the Penis. A Clinico-Pathological Study of 14 Cases (769) EF Velazquez, J Melamed, JE Barreto, F Aguero, AL Cubilla - New York University Medical Center, New York, NY; Instituto de Patologia e Investigacion, Asuncion, Paraguay 93 Carcinoma Cuniculatum of the Penis: A Distinctive Deeply Invasive Variant of Verrucous Carcinoma. A Report of 6 Cases (583) JE Barreto, EF Velazquez, E Ayala, AL Cubilla - Instituto de Patologia e Investigacion, Asuncion, Paraguay; New York University Medical Center, New York, NY 94 Prognostic Factors in Penile Carcinoma (727) MP Revelo, N Bradford, JA Smith, SB Shappell, MS Cookson - Vanderbilt University Medical Center, Nashville, TN